MedTrace Logo

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

NCT07573943 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-05-07

No results posted yet for this study

Summary

Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overall clinical cure rate to more than 50% without screening specific advantageous groups.

Conditions

Interventions

DRUG

Anti-PD-L1 antibody (ASC22)

Once two weeks, 1mg/kg, subcutaneous injection

DRUG

Nucleotide analogs

Once/day, 1 capsule/time, oral

DRUG

Peg-IFNα

Once/week, 180μg/time, subcutaneous injection

Sponsors & Collaborators

  • First Affiliated Hospital of Chongqing Medical University

    collaborator OTHER

  • Three Gorges Hospital of Chongqing University

    collaborator OTHER

  • Guizhou Provincial People's Hospital

    collaborator OTHER

  • The Second Affiliated Hospital of Chongqing Medical University

    lead OTHER

Principal Investigators

  • Hong Ren, MM · The Second Affiliated Hospital of Chongqing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-21
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07573943 on ClinicalTrials.gov